Nadrich Accident Injury Lawyers represents those who have developed Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) after taking a GLP-1 drug such as Ozempic.
We are representing those who have developed NAION after taking any of the following drugs:
- Ozempic
- Wegovy
GLP-1 receptor agonists such as Ozempic or Wegovy have become extremely popular for weight loss and blood sugar control in recent years. However, scientific studies have linked the diabetes and weight loss drugs with NAION, a rare eye disease which can cause sudden blindness which is permanent and often in one eye.
The number of lawsuits alleging that GLP-1 drugs have caused NAION continues to grow. The lawsuits filed allege that drug manufacturers failed to warn users about the NAION risks associated with their drugs.
Our law firm has been representing victims of dangerous drugs since 1990. Our vast experience in taking on pharmaceutical companies will allow us to fight for fair compensation for you.
We are handling GLP-1 drug vision loss claims on a contingency fee basis, meaning we will not charge you any fee until we win your case. The only fee which the Ozempic lawyers at our firm will charge you is a percentage of any compensation we recover for you. You will owe us zero out-of-pocket costs.
Call us today for a FREE consultation at (800) 718-4658 or fill out our quick contact form if you or a loved one has developed NAION after taking a GLP-1 medication such as Ozempic.
Results We and Our Partners Have Obtained in Dangerous Drug Cases
Table of Contents
- Latest Update
- Can Ozempic Cause NAION?
- What Is NAION?
- The Symptoms of NAION
- How Long After Starting Semaglutide Does NAION Start?
- Who Qualifies for an Ozempic Lawsuit?
- How Much Does the Ozempic Lawsuit Pay Out?
- What Do Ozempic Blindness Lawsuits Allege?
- Does Ozempic Affect Your Eyesight?
- Has Anyone Gone Blind on Ozempic?
- Is Vision Loss From Ozempic Reversible?
- Statute of Limitations for an Ozempic Vision Loss Lawsuit
- How Nadrich Accident Injury Lawyers Can Help With Your Ozempic Blindness Lawsuit
- Contact Us to File an Ozempic NAION Lawsuit Today
- Ozempic Blindness Lawsuit Updates
Latest Update
September 8, 2026 Update
A lawsuit filed on August 27 in Pennsylvania by an Indiana woman alleges that she and her doctor weren’t warned that injections of Ozempic could lead to vision loss when she received a prescription for the medication for the lowering of blood sugar.
The lawsuit names Novo Nordisk A/S and Novo Nordisk Inc. as defendants and will be consolidated alongside hundreds of similar lawsuits.
The lawsuit is just one of many that allege that manufacturers like Novo Nordisk didn’t warn that GLP-1 drugs such as Ozempic, Wegovy and Mounjaro can cause permanent, sudden loss of vision.
The lawsuit claims the woman was prescribed the drug in May 2024 for the controlling of type 2 diabetes and the lowering of blood sugar. It is alleged that, one morning, she woke up, discovering she had significant vision loss.
The woman stopped receiving Ozempic injections, but her doctors allegedly told her that her vision loss is probably permanent.
The lawsuit claims that the failure to warn by Novo Nordisk about the risk of loss of vision wasn’t accidental, but was rather intentional, in order to protect the sales of GLP-1 drugs.
The lawsuit alleges Novo Nordisk didn’t update their drugs’ warning labels and didn’t properly alert doctors that those taking the drugs could require monitoring for signs of vision loss, which might let treatment get stopped prior to additional damage happening.
Can Ozempic Cause Blindness?
Numerous scientific studies have linked GLP-1 drugs such as Ozempic with and increased risk of vision loss, specifically NAION.
- A study published in March 2025 concluded that its results suggested an association between semaglutide use and a higher risk of developing NAION in those with diabetes. The study found that those taking semaglutide had 2.39 times the risk of developing NAION at the two year mark after being prescribed semaglutide, 2.44 times the risk at the three year mark and 2.05 times the risk at the four year mark. The study involved 3,344,205 diabetes patients, including 174,584 patients who took semaglutide.
- A study published in February 2025 concluded that semaglutide is associated with a “modest” increase in the risk of developing NAION in those with type 2 diabetes. The study found that exposure to semaglutide is associated with 1.32 times the risk of developing NAION. The study involved 37.1 million people with type 2 diabetes, including 810,390 new users of semaglutide.
- A study released in December 2024 found that those with type 2 diabetes who took semaglutide, the active ingredient in Ozempic, were more than twice as likely to develop NAION than those who did not. The study examined a Danish cohort consisting of 424,152 type 2 diabetes patients. 106,454 of the patients took semaglutide once per week and 317,698 patients did not. The patients who developed NAION developed the condition between about 10 months and about 38 months after being prescribed the drug, with the median time being 22.2 months.
- A study published in August 2024 concluded that its findings suggested a link between NAION and semaglutide. The study examined a cohort of 16,827 patients who were overweight, had obesity or had type 2 diabetes. The study found that type 2 diabetes patients taking semaglutide were 4.28 times more likely to develop NAION than patients not taking semaglutide. The study also found that overweight or obese patients taking semaglutide were 7.64 times more likely to develop NAION than patients not taking semaglutide.
In addition, the safety committee of the European Medicines Agency concluded that NAION is a side effect of medicines containing semaglutide, including Ozempic and Wegovy.
Manufacturers of GLP-1 drugs such as Novo Nordisk, Ozempic’s manufacturer, are now facing numerous lawsuits which allege a link between the drugs and NAION.
The lawsuits accuse the manufacturers of not adequately warning healthcare providers and patients about the possible vision loss risk associated with usage of the drugs. The lawsuits claim that the drugs’ labels don’t sufficiently address the risk, even though adverse event reports and scientific evidence are mounting, suggesting that the drugs are connected to optic nerve damage.
What Is NAION?
NAION is an eye condition which is the result of blood flow to the optic nerve being blocked. It leads to painless, sudden vision loss, usually in a single eye.
Here’s a detailed look at NAION:
- Doctors aren’t sure what causes most cases of NAION. However, they think it might be related to sleep apnea as well as some medications, like sildenafil (Viagra) or semaglutide (Ozempic).
- Sleep apnea may lead to blood pressure increases, intracranial pressure or low levels of oxygen in the blood at night. This may lead to a buildup of fluid and not enough oxygen getting to the optic nerve.
- Health conditions like hypertension, diabetes, endothelial dysfunction, atherosclerosis, small cup-to-disc ratio, hyperlipidemia and metabolic syndrome can increase the risk of developing NAION.
- “Ischemia” refers to a body part not getting enough oxygen due to restricted blood flow. In NAION’s case, the optic nerve is affected by the lack of oxygen.
- NAION may be accompanied by optic disc hemorrhage, acute optic disc swelling, chronic optic nerve deterioration and altitudinal field loss
- Diagnosing NAION involves measuring visual acuity, color vision, pupils and peripheral visual fields. Doctors also check the appearance of the optic disc and retina.
- There is not currently any surgical or medical treatment demonstrated to improve the prognosis of acute NAION.
- Research is being done on neuroregenerative and neuroprotective treatments like optic nerve regeneration, retinal ganglion cell transplantation and stem cell therapy.
- The condition of about 70 percent of NAION patients remains the same after diagnosis. 20 percent experience modest visual acuity improvement. 10 percent go through progressive worsening during the four weeks after diagnosis, but stabilize within two months.
- When people develop NAION in one eye, about 15 percent of them develop NAION in the other eye within five years.
The Symptoms of NAION
NAION symptoms include:
- Painless, sudden loss of vision in a single eye – this often looks like worsened vision or blurring across only a part of your visual field, typically in the lower half
- Cloudiness or blurring, often while looking down
- Color vision deficiency
- Loss of contrast
- A shadowed or dark area in one’s visual field
- Rarely, pain near the eye or headache
How Long After Starting Ozempic Does NAION Start?
Studies on the possible association between NAION and GLP-1 drugs like Ozempic have led to varying findings about NAION development’s timeframe after starting on the medication.
- Mixed results: Some studies have suggested that the risk of developing NAION may be the highest during the first year of treatment. Other studies found that the risk ended up increasing as treatment went on, specifically between the second and fourth year of treatment.
- Median onset: One study found that the median time from semaglutide prescription to NAION development was 22.2 months.
- Consistent across time: NAION’s onset has been found to develop during the whole period of observation, meaning it can possibly occur at any time during treatment.
Who Qualifies for an Ozempic Lawsuit?
You may qualify for financial compensation in an Ozempic NAION lawsuit if you or a loved one experienced sudden vision loss or were diagnosed with NAION after taking any of the following medications:
- Ozempic
- Wegovy
How Much Does the Ozempic Lawsuit Pay Out?
There have not been any official settlements in the Ozempic litigation as of July 2025.
The potential compensation in an Ozempic blindness lawsuit may significantly vary, ranging from just a few thousand dollars to millions of dollars, depending upon injury severity and additional factors.
The value of your potential Ozempic settlement or judgment will vary, based upon the circumstances of your case. Factors which can influence the value of your case include:
- Injury severity: Patients with more severe vision loss may be eligible for larger amounts of compensation.
- Use duration: Patients who took Ozempic or other GLP-1 drugs for longer might qualify for additional compensation.
- Medical bills: Plaintiffs who incur significant medical expenses due to their vision loss may qualify to recover past and future medical costs, including compensation for the cost of diagnosis, surgery, treatments, vision therapy and medication.
- Lost wages: Plaintiffs who miss work or lose income due to vision loss might qualify to recover financial compensation for these monetary losses.
- Loss of earning capacity: If you find yourself unable to work anymore due to your vision loss, or unable to do the job you used to, you may qualify for compensation for the resulting loss or reduction of your earning capacity.
- Pain and suffering: Plaintiffs might qualify to recover financial compensation for physical pain, mental suffering and emotional distress.
- Lost quality of life: The impact upon the plaintiff’s ability to enjoy their life, participate in hobbies, and maintain relationships will affect the value of a case.
- Legal representation: It is crucial to consult with an experienced Ozempic attorney, and the quality of your lawyer can affect the value of your case. A lawyer can assess your case details, help you to understand your claim’s potential value, and guide you through the entire legal process.
What Do Ozempic Blindness Lawsuits Allege?
- NAION: Lawsuits allege that plaintiffs have developed sudden, permanent vision loss due to NAION after taking GLP-1 drugs like Ozempic.
- Other vision changes: Lawsuits have also addressed additional claims of changes in vision, such as color distortion, loss of contrast and blurred vision.
- Failure to warn: Lawsuits claim that drug makers didn’t adequately warn about the risks of NAION and vision loss despite reports and studies which suggested a possible link.
- Aggressive marketing: Lawsuits claim that drug makers aggressively marketed their products, including the promotion of drugs for the purpose of off-label weight loss, despite not fully disclosing possible risks.
- Unreasonable risk: Lawsuits argue that potential vision loss constitutes an unreasonably dangerous side effect which drug makers should have mentioned in stronger warnings.
- Lobbying efforts: A lawsuit alleges that Novo Nordisk engaged in lobbying efforts in order to push Ozempic to a broader market via partnering with telemedicine companies.
Does Ozempic Affect Your Eyesight?
In addition to NAION, GLP-1 drugs such as Ozempic have been linked with:
- Blurred vision: Some patients taking GLP-1 drugs have experienced blurred vision as a result of macular edema. In addition, blood sugar level changes can affect your eye lens’ shape, temporarily leading to blurry vision. This side effect is typically temporary and resolves when your body adjusts to the drug.
- Worsening diabetic retinopathy: Those with type 2 diabetes can experience high blood sugar levels. This can cause the eye’s blood vessels to leak, leading to diabetic retinopathy. Some patients taking GLP-1 drugs have experienced worsening diabetic retinopathy.
- Macular complications: Some patients taking GLP-1 drugs have ended up developing macular edema. This is when fluid builds up in the macula, which is an area in the retina’s center responsible for straight-ahead, sharp vision.
- Cataract growth: Evidence suggests that GLP-1 drugs administered weekly can indirectly influence cataract growth.
It is important to consider the following:
- Individual variability: Not every GLP-1 drug patient will experience changes in vision. Some people may be more susceptible to vision changes than others.
- Risk factors: Those with diabetes, particularly those who have pre-existing eye conditions, might be at a greater risk.
- Consult with a doctor: If you experience vision changes while taking Ozempic or another GLP-1 drug, it’s vital to have a consultation with a doctor or ophthalmologist in order to determine the cause as well as the proper course of action.
- Benefits and risks: While vision loss risks exist, GLP-1 drugs like Ozempic can effectively manage weight loss and blood sugar. Talk about the possible risks and benefits with a doctor so you can make a decision which is informed. Don’t stop taking a GLP-1 drug like Ozempic without first talking to a doctor.
Has Anyone Gone Blind on Ozempic?
Numerous lawsuits now allege that patients who have taken GLP-1 drugs like Ozempic have suffered severe vision loss:
- A lawsuit filed on April 24, 2025 in New Jersey alleges that a Maryland man became legally blind due to NAION after taking Ozempic. According to the lawsuit, the man first experienced vision loss in one eye before eventually developing legal blindness in both. The man was allegedly forced to quit his job as a county public works department motor equipment operator.
- A lawsuit filed in New Jersey on July 2, 2025 alleges that the plaintiff lost 85 percent of vision in his left eye due to NAION after taking Ozempic from November 2021 to January 2022.
- In April 2025, it was reported that a grandmother of 11 was suing Novo Nordisk over NAION and vision loss which she developed after taking Wegovy and Ozempic. She said that it hurts to think about not being able to fully see the faces of her grandchildren. She alleges that she is no longer to work at the bank she used to work at due to permanent vision loss.
- It was reported in April 2025 that a New Jersey man developed bilateral NAION and permanent vision loss after taking a GLP-1 drug manufactured by Novo Nordisk. The man’s lawsuit claims that he can’t drive anymore, can’t read anymore, and is totally dependent upon his wife for assistance from day to day.
- A New Jersey man has filed a lawsuit which claims he developed NAION and vision loss due to taking Ozempic. The man claims he had to quit his work as a general contractor due to severely blurred vision.
- In May 2025, it was reported that a New York man was suing Novo Nordisk, alleging he developed partial vision loss due to NAION after taking Ozempic. The man, who claimed to have 20/20 vision prior to taking the drug, said that if he closes his left eye, faces get blurry and he can’t read his smartphone.
- A lawsuit filed in New Jersey on June 6, 2025 claims that the plaintiff suffered from blurred vision and vision loss in his right eye due to NAION “as a result” of using Wegovy and Saxenda.
- A lawsuit filed in New Jersey on April 16, 2025 alleges that the plaintiff suffered from blurred vision and vision loss in her left eye due to NAION “as a result” of Ozempic use.
- A lawsuit which was filed on April 29, 2025 in New Jersey claims that the plaintiff suffered blurred vision and vision loss in his right eye due to NAION after taking Wegovy.
Is Vision Loss From Ozempic Reversible?
Vision loss associated with GLP-1 medications like Ozempic, especially sudden vision loss, can be very concerning and often can’t be reversed.
GLP-1 drugs like Ozempic can cause blood sugar fluctuations which lead to blurry vision which is only temporary. However, this is not the same as the severe, sudden vision loss which is caused by NAION.
NAION generally causes irreversible vision loss, meaning the lost vision is permanent. While treatments can help to slow progression or manage symptoms, it is unlikely that the loss of vision will be fully restored.
Statute of Limitations for an Ozempic Vision Loss Lawsuit
There is a time limit for you to file a lawsuit if you have developed NAION after taking a GLP-1 medication such as Ozempic. This time limit is known as a statute of limitations and the time limit will vary from state to state.
For example, in California, the time limit to file a lawsuit involving an injury caused by a medication is two years from the date you discovered that your injury was caused by the medication.
Failing to file a lawsuit in time can forever prevent you from recovering compensation for your vision loss.
Contact a lawyer as soon as possible to avoid missing the window to file a claim. In addition, it can take quite a bit of time to put together a strong, convincing case in a drug liability lawsuit. Calling an Ozempic lawyer today will give your lawyer the best opportunity to put together the strongest case possible for you.
How Nadrich Accident Injury Lawyers Can Help With Your Ozempic Eyesight Lawsuit
Our lawyers can help you by:
- Investigating your case: We can collect crucial evidence like drug labels, medication packaging, receipts, prescription records, medical records, research studies and expert opinions from pharmacological and medical professionals. We will meticulously examine your medical records in order to understand your injury’s extent and its connection to the GLP-1 drug.
- Identifying liable parties: We can determine whether a pharmaceutical company, distributor, manufacturer or even a prescriber is liable for your damages.
- Building a strong case: We can create a compelling argument which is supported by expert testimony and evidence in order to demonstrate that your vision loss was caused by a GLP-1 medication such as Ozempic.
- Working with experts: We work with medical professionals in order to understand drugs’ effects, potential risks and manufacturing processes.
- Gathering witness testimonies and statements: We will gather and present witness testimonies and statements from other people who have been harmed by the same drug that you were.
- Collecting evidence during discovery: During the discovery phase, we will obtain internal company documents such as marketing materials, clinical trial results and testing data to support your case.
- Handling everything for you: We can take care of all the legal paperwork for you, making sure you meet all legal deadlines.
- Negotiating with pharmaceutical companies or insurance providers: We can seek a fair settlement in order to cover medical bills, lost wages, physical pain and mental suffering that resulted from a GLP-1 drug.
- Representing you in court: If we can’t reach a settlement, we will represent you in court in order to pursue justice and financial compensation.
- Representing you at no out-of-pocket cost: We will only charge you a fee if we win your case and will not charge you any out-of-pocket fees.
Contact Us to File an Ozempic NAION Lawsuit Today
Our lawyers have been helping those injured by dangerous drugs such as Ozempic for over 35 years. We have extensive experience handling cases just like yours. We may also be able to help you recover compensation if you’ve experienced other side effects as a result of taking Ozempic or other GLP-1 drugs.
You won’t owe us a single penny if we don’t win your case, as our only fee is a percentage of any money that we recover for you.
Let us hold the drug manufacturer responsible for your vision loss and recover justice and compensation for you. Call us today for a FREE consultation at (800) 718-4658 or fill out our convenient contact form if you or a loved one developed NAION after taking a GLP-1 medication such as Ozempic.
Ozempic Blindness Lawsuit Updates
August 4, 2026 Update
A lawsuit filed on July 28 in Pennsylvania by a Florida woman alleges that the woman suddenly lost her eyesight after she was prescribed Ozempic for diabetes.
The lawsuit names Novo Nordisk A/S and Novo Nordisk Inc. as defendants.
The woman alleges that, due to using Ozempic for under two years, she developed non-arteritic anterior ischemic optic neuropathy (NAION), leading to permanent vision loss.
The complaint alleges she was prescribed the drug for type 2 diabetes in September of 2019, and continued using it until January 2021, when she experienced sudden vision loss.
The complaint notes that no label warning linked Ozempic with a risk of NAION, despite Novo Nordisk allegedly knowing for a long time about the possible vision risks. The lawsuit notes that the prescribing information for the drug has been revised 13 times since it was approved, yet none of the updates warned patients or doctors about a risk of NAION.
The lawsuit claims the vision loss is permanent, claiming she will never again see clearly because she used Ozempic.
July 19, 2026 Update
The judge presiding over the Ozempic NAION MDL has directed the parties to focus their early discovery on if plaintiffs are able to establish that GLP-1 medications’ side effects can lead to vision loss, as well as if federal law preempts failure-to-warn claims.
The plaintiffs wished to go straight into the main discovery process in order to promote efficiency and start preparing test cases for early trial. The defendants, however, requested a period of early discovery focusing on general causation and federal law preemption.
The judge agreed with the defense. She disagreed that early discovery could significantly slow down the litigation, noting the defendants have suggested that fact discovery should be completed by October 2026, and that the end of 2026 should see expert discovery completed.
May 18, 2026 Update
A study published in Jama Network Open is providing additional evidence that drugs such as Wegovy and Ozempic might cause a rare eye disease which leads to sudden, potentially permanent loss of vision.
The data appears to confirm prior findings that link GLP-1 drugs with a higher risk of developing NAION, a condition which causes damage to the optic nerve, possibly leading to issues such as blurred vision or blindness.
The researchers investigated 588,168 participants, 139,549 of whom took GLP-1 drugs and 448,622 of whom took a type of SGLT2 inhibitors. The researchers found that those taking the GLP-1 drugs had a 35 percent higher risk of developing NAION than those taking the SGLT2 inhibitors.
The researchers have urged that healthcare providers heighten their vigilance for early NAION signs in GLP-1 users.
May 8, 2026 Update
A lawsuit filed on April 27 in Pennsylvania by a Massachusetts man alleges the man suffered permanent vision loss because of Ozempic side effects.
The lawsuit names Novo Nordisk A/S and Novo Nordisk Inc. as defendants.
The lawsuit claims the man’s use of the drug led to vision loss in both of his eyes.
According to the complaint, the man started using Ozempic in April of 2024 and kept using it until May of 2025.
The lawsuit claims he developed NAION because of using Ozempic, leading to vision loss in both eyes.
The plaintiff claims he could have avoided vision loss had Novo Nordisk been truthful and transparent about the drug’s side effects. Instead, he alleges the company hid evidence of possible health problems.
The lawsuit notes that Novo Nordisk didn’t just fail to warn consumers about NAION, but failed to warn consumers about bowel obstructions and stomach paralysis as well.
March 6, 2026 Update
A lawsuit filed on February 20 in Missouri by a Missouri woman alleges that the woman’s vision was permanently damaged by injections of Ozempic, significantly impairing her quality of life.
The lawsuit alleges that the injections led to her developing NAION.
The lawsuit joins a growing number of lawsuits alleging that Novo Nordisk failed to warn that Ozempic’s side effects might cause permanent, sudden vision changes such as blindness.
A study published in February in JAMA Ophthalmology found that those treated with semaglutide-based medications such as Ozempic face about double the risk of developing NAION compared to those who use SGLT2 inhibitor drugs.
The lawsuit alleges that the woman was prescribed Ozempic in February 2024 and signs of an issue emerged in July of that year. The woman noticed a smudge in her visual field and was diagnosed with NAION by an ophthalmologist.
The lawsuit alleges she continues suffering from decreased vision in her eye and blurry vision, and that this negatively affects her job and daily life.
The lawsuit claims she has suffered from blurry vision, nerve pain, optic nerve swelling and visual disturbance.
The lawsuit alleges Novo Nordisk has known about a NAION risk for years but placed profits over the safety of patients.
February 17, 2026 Update
A lawsuit filed on February 3 in Pennsylvania by an Ohio man alleges that he developed severe vision loss due to taking Ozempic, leading to “radical” changes in quality of living and his life.
The lawsuit alleges that his use of Ozempic caused him to develop non-arteritic anterior ischemic optic neuropathy (NAION).
The lawsuit claims that Novo Nordisk failed to adequately warn the public about the risks associated with the drug, and did this even though they knew or should have known about the risks, choosing to place profit over patient safety.
The lawsuit alleges the man was prescribed Ozempic in February of 2023, then, in January 2024, started to experience vision loss in one eye. By the time he was referred to an ophthalmologist, his vision in that eye had allegedly deteriorated to the point he could only see his hands’ motion.
A specialist diagnosed him with NAION and told him it’s permanent.
The lawsuit notes that numerous studies link GLP-1 drugs like Ozempic with NAION, and argues that Novo Nordisk should have known about the link because of the existence of these studies.
The lawsuit notes that the first time vision issues were linked with GLP-1 drugs was 2012, and that even Novo Nordisk’s own trials indicated that a “non-statistically insignificant” risk of optic ischemic neuropathy was associated with the drug.
January 21, 2026 Update
A lawsuit filed on January 15 in Pennsylvania by a California man alleges that the man suffered severe eyesight loss after receiving injections of Ozempic, leading to huge lifestyle changes.
The lawsuit alleges that Novo Nordisk and its subsidiaries failed to warn the medical community and consumers about Ozempic’s true risks.
The lawsuit joins almost two dozen GLP-1 vision loss lawsuits as well as over 2,900 GLP-1 gastroparesis lawsuits.
The lawsuit alleges the man received injections of Ozempic beginning in August 2023, but started experiencing flashes and blurred vision in his right eye in February 2024.
According to the lawsuit, the man then saw an ophthalmologist and was diagnosed with nonarteritic anterior ischemic optic neuropathy (NAION).
While the man has stopped taking the drug, he claims his loss of eyesight is permanent.
The lawsuit alleges that the drug’s manufacturer knew or should have known that the drug could cause vision loss, noting that Novo Nordisk knew since 2016 at the latest that GLP-1 receptors are in the human eye.
The lawsuit noted that optic ischemic neuropathy has been linked with GLP-1 drug use since 2012, and has been linked with Wegovy and Ozempic since 2019, years prior to the man being prescribed Ozempic.
The lawsuit also accuses Novo Nordisk of knowing about NAION risks at the time of Ozempic’s clinical trials.
A 2024 study found that those receiving GLP-1 drugs are over four times as likely to end up with NAION compared with those not treated with GLP-1 drugs.
December 19, 2025 Update
A panel of federal judges has agreed that all vision side effect lawsuits concerning GLP-1 drugs like Ozempic and Wegovy will be consolidated in an MDL in Pennsylvania’s Eastern District.
The claims will be centralized before the same judge who is handling the GLP-1 gastrointestinal side effect MDL.
However, the vision loss claims will be consolidated into an MDL that is separate from the one involving the gastrointestinal side effect claims.
The panel noted that having the same judge oversee both MDLs will be efficient, since there will likely be significant overlap regarding the vision loss lawsuits and gastrointestinal side effect lawsuits, and since the cases involve mostly the same counsel and same defendants.
October 7, 2025 Update
The United States Judicial Panel on Multidistrict Litigation is being asked by plaintiffs to create a new federal MDL for GLP-1 drug vision loss lawsuits instead of grouping them into the mass tort which has been established for claims which involve gastrointestinal injuries like stomach paralysis.
There are around 3,000 lawsuits involving GLP-1 drugs like Ozempic and allege that the drugs’ manufacturers failed to warn about the risk of stomach paralysis. However, the number of GLP-1 drug claims involving NAION is steadily growing.
Eli Lilly filed a motion in August asking for the NAION claims to be consolidated in the same MDL as the gastroparesis claims. According to this motion, at least 21 NAION lawsuits had been filed already in three federal districts.
However, last month, plaintiffs filed a memorandum in opposition to Eli Lilly’s request, arguing that a different judge should handle them in a different venue. They are arguing that consolidating these cases into the gastroparesis MDL would harm, not enhance efficiency.
The plaintiffs are objecting to the NAION claims having to “get in line behind” the gastrointestinal claims which involve “fundamentally different” evidence and core allegations.
The memorandum is calling for the cases to be handled in New Jersey, where 17 cases have been filed.
July 14, 2025 Update
A lawsuit was filed in New Jersey on July 2 by a New York man who alleges that Ozempic’s makers knew or should have known that Ozempic could cause users to end up with a rare eye disease which can lead to sudden, incurable blindness.
The lawsuit alleges that Novo Nordisk failed to warn people that evidence such as post-marketing studies and clinical trials showed that Ozempic is linked with non-arteritic anterior ischemic optic neuropathy (NAION).
This disease is caused by a reduction in the flow of blood to the optic nerve. This can lead to sudden vision loss which is painless and can be permanent.
The lawsuit indicates the plaintiff used Ozempic from November 2021 until January 2022, and lost about 85 percent of his left eye’s vision.
The lawsuit alleges that Novo Nordisk had data from adverse event reports, post-market surveillance studies, premarket clinical trials, and pre-clinical trials which should have shown them that Ozempic was linked with NAION.
The lawsuit also alleges that Novo Nordisk spent huge sums of money marketing Ozempic while misrepresenting and withholding info which was obtained following FDA approval about potential side effects.
June 23, 2025 Update
Plaintiffs Requesting Multicounty Litigation for Vision Loss Claims
Novo Nordisk is now facing enough claims which involve vision loss that some plaintiffs are asking them to be consolidated into a multicounty litigation in New Jersey. The litigation would place all New Jersey Ozempic vision loss cases under a single judge, which plaintiffs say would serve the convenience of witnesses, courts and parties.
The plaintiffs claim there are now 21 Wegovy or Ozempic vision loss lawsuits spread across eight separate judges in New Jersey. Novo Nordisk is headquartered in New Jersey.
Study Finds Link Between GLP-1 RAs and Eye Condition
A new study has found a link between GLP-1 RA drugs like Ozempic and neovascular age-related macular degeneration (nAMD), a condition which can lead to severe, rapid vision loss.
The researchers found that those who took the drugs were twice as likely to develop nAMD than those who didn’t take them.
The researchers investigated the outcomes of 139,002 diabetes patients, including 46,334 who took GLP-1 RA drugs like Ozempic and 92,668 who did not.
June 15, 2025 Update
A lawsuit was filed on June 6 in New Jersey by a Massachusetts woman who alleged that she suffered blurry vision and vision loss in her right eye due to taking the GLP-1 receptor agonist drugs Wegovy and Saxenda.
The lawsuit alleges she started using Saxenda in December of 2022 and kept using it until May of 2023. In June of 2023, she started using Wegovy, which she used until January of 2024.
The complaint alleges she started experiencing side effects of non-arteritic anterior ischemic optic neuropathy (NAION) because of the use of the drugs, leading to blurred vision and vision loss. This has caused severe, permanent vision issues, the lawsuit alleges.
The lawsuit alleges that the injuries may have been avoided if Novo Nordisk had adequately warned the medical community and consumers about the risks of NAION associated with Wegovy and Saxenda.
The lawsuit alleges that Novo Nordisk made efforts to minimize or conceal the risks associated with the drugs.
May 26, 2025 Update
Over a dozen lawsuits have gotten filed by users of weight-loss drugs such as Ozempic, claiming the drugs have led to vision loss.
Patients from New Jersey and New York have alleged they developed non-arteritic anterior ischemic optic neuropathy (NAION) after taking medications which contain semaglutide, the active ingredient in Wegovy and Ozempic. This is a rare condition which leads to lost blood flow to the optic nerve, causing one eye to experience sudden vision loss.
A lawyer has claimed that one of his clients has lost vision in both eyes.
A New Jersey resident allegedly started taking Ozempic in October 2022 and was diagnosed with NAION around eight months later. He allegedly wasn’t able to perform his job any longer due to his vision loss.
May 8, 2025 Update
A lawsuit was filed on April 29 in New Jersey by an Illinois man who alleges that he developed permanent vision issues because he took Wegovy.
The lawsuit alleges the man took Wegovy injections for around a year, beginning in June 2023, then developed non-arteric anterior ischemic optic neuropathy, a condition involving the optic nerve suffering from not enough blood flow. The lawsuit alleges this caused him to experience vision loss and blurred vision.
The lawsuit claims that Novo Nordisk, the manufacturer of Wegovy, knew or should have known about the risk of vision issues associated with the drug but failed to warn about it.
